Status:
COMPLETED
The Benefit and Harm of Fever Suppression by Antipyretics in Influenza
Lead Sponsor:
The University of Hong Kong
Conditions:
Influenza
Eligibility:
All Genders
18-30 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to investigate the potential benefits and risks of antipyretics use in naturally occurring influenza virus infections in humans.
Detailed Description
Background: Being one of the commonest conditions encountered in modern medical practice, fever is commonly regarded as an illness that has to be treated, both by medical professionals and patients. ...
Eligibility Criteria
Inclusion
- Adults aged between 18-30
- Presenting with symptoms of acute URTI (at least two among the following symptoms: body temperature ≥37.8°C, cough, rhinorrhea, sore throat, headache, myalgia/arthralgia) within 48 hours of illness onset
- being tested positive with a QuickVue rapid influenza test
Exclusion
- Allergic to paracetamol or any other antipyretics
- Have any underlying immunocompromized condition or be receiving immunosuppressive agents.
- Have any history of chronic liver disease, or any active lung, heart or renal diseases requiring regular medication.
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2018
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT01891084
Start Date
July 1 2013
End Date
December 1 2018
Last Update
January 31 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Health Service, The Hong Kong Polytechnic University
Hong Kong, Hksar, China